Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Objectives: (1) To develop a clinically useful model with which dermatologists can understand the potential uses of biologic therapy for psoriasis and understand the potential differences among these ...

Drs Steven Feldman and Tina Bhutani-Jacques explore how next-generation oral therapies are closing the gap with biologics and ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas ...

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Patient-reported outcomes, including disease burden and HRQoL, significantly influence treatment switching in plaque psoriasis. Even patients with low clinician-assessed severity may switch to ...

J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.

Black Medicaid beneficiaries were less likely to use biologics compared with white beneficiaries in a cross-sectional study. Compared with white beneficiaries, Black beneficiaries had lower biologic ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...